ProCE Banner Events

Share

An Interactive Case-Based Review of Chronic Lymphocytic Leukemia: Experts Explore the Latest Evidence and Guideline Updates

In collaboration with the NCCN, join us for this dynamic, case-based, CME/CE/CPE-certified live symposium, in which an expert panel will discuss current recommendations and emerging strategies for treating patients with CLL. Sign up now!

Friday Satellite Symposium preceding the 66th ASH Annual Meeting and Exposition.

Evaluation link: education.nccn.org/CLL-symposium

Physicians ABIM MOC: maximum of 2.00 Medical Knowledge MOC points

Physician Assistants: maximum of 2.00 hours of AAPA Category 1 CME credits

Registered Nurses: 2.00 Nursing contact hour

Pharmacists: 2.00 contact hours (0.2 CEUs)

Physicians: maximum of 2.00 AMA PRA Category 1 Credits

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for hematologists, oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Time and location

Friday, December 06, 2024

7:00 AM - 9:30 AM Pacific Time (PT)

In-person

7:30 AM - 9:30 AM Pacific Time (PT)

Virtual

Manchester Grand Hyatt San Diego
1 Market Pl.
San Diego, California 92101

Grand Hall C

Agenda

Registration & Breakfast: 7:00 AM - 7:30 AM PT

 

NCCN Guidelines Review for First-line and Later-line Treatment Strategies

Key Variables in Deciding Between Regimens

Mastering the Current Regimen Components: MOA, Key Efficacy and Safety Data, and Additional Considerations With BTK Inhibitors, BCL-2 Inhibitors, and CAR T-Cell Therapy

Interactive Case Challenges Across Lines of Therapy: Putting It All Together for effective Management of CLL

Novel Therapeutic Strategies on the Horizon

Highlighting Key CLL Abstracts From ASH 2024

Question and Answer Session

Location

Venue Name

Manchester Grand Hyatt San Diego

Address

Manchester Grand Hyatt San Diego
1 Market Pl.
San Diego, California 92101

Room Name

Grand Hall C

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Target Audience
This program is intended for hematologists, oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference
  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action
  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (e.g. assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)
  • Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 2.0 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.20 CEUs) of continuing education credit. UAN: JA4008196-0000-24-094-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

LogoDescription automatically generated

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification 

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 

Acknowledgement

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.